Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4360275 | 0.98 | TSHR (0.34) | TSHRLMNA | |
| Hydrochloric Acid SCHEMBL10603611 | 0.98 | TSHR (0.34) | TSHRLMNA | |
| SCHEMBL7808818 | 0.85 | LMNA (0.32) | LMNA | |
| SCHEMBL97780 | 0.78 | TSHR (0.56) | TSHRLMNA | |
| SCHEMBL2863391 | 0.76 | FOLH1 (0.32) | TSHRLMNA | |
| Hydrochloric Acid SCHEMBL180144 | 0.75 | TSHR (0.53) | TSHRLMNA | |
| Hydrochloric Acid SCHEMBL1844352 | 0.75 | TSHR (0.53) | TSHRLMNA | |
| SCHEMBL19308751 | 0.72 | — | — | |
| SCHEMBL9008493 | 0.71 | TSHR (0.56) | TSHRLMNA | |
| SCHEMBL163253 | 0.71 | TSHR (0.72) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1125 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299383-B1 | SPECIFIC MODIFICATION OF ANTIBODY WITH IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2025-12-03 | — | — | EP | claimed |
| EP-3470418-B1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2024-07-31 | — | — | EP | claimed |
| EP-3505628-B1 | METHOD FOR CONCENTRATING MICROORGANISM OR EXTRACTING NUCLEIC ACID USING DTBP | INFUSION TECH (KR) | 2023-05-03 | — | — | EP | claimed |
| EP-1392255-B1 | NANOPARTICLES MADE OF PROTEIN WITH COUPLED APOLIPOPROTEIN E FOR PENETRATION OF THE BLOOD-BRAIN BARRIER AND METHODS FOR THE PRODUCTION THEREOF | LOHMANN THERAPIE SYST LTS (DE) | 2011-06-08 | — | — | EP | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| US-6436705-B1 | TREATING WITH CARBON MONOXIDE GAS AND REVERSIBLE CROSSLINKING AGENT OF DIAMIDE OR DIMETHYL-3,3*-DITHIOBISPROPIONIMIDATE IN PRESENCE OF GLUCOSE, FRUCTOSE, SUCROSE, TREHALOSE, OR RAFFINOSE CRYOPROTECTANT; FREEZE DRYING; STORAGE STABILITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-08-20 | — | — | US | claimed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | claimed |
| US-6358678-B1 | TREATING ERYTHROCYTES WITH CARBON MONOXIDE GAS, REACTING WITH REVERSIBLE CROSSLINKING AGENT IN PRESENCE OF HIGH CONCENTRATION OF LOW MOLECULAR WEIGHT CRYOPROTECTANT, LYOPHILIZING, STORING AT ROOM TEMPERATURE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-03-19 | — | — | US | claimed |
| WO-2001046461-A2 | MODIFIED NUCLEIC ACIDS AND THEIR USE | BIOCHIP TECHNOLOGIES GMBH (DE) | 2001-06-28 | — | — | WO | claimed |
| EP-1111069-A1 | Modified nucleic acids and their use | BioChip Technologies GmbH (DE) | 2001-06-27 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-5874083-A | PROTEINS AND COMPLEXES FOR IMMUNE RESPONSE | BIOENTERPRISES PTY LIMITED (AU) | 1999-02-23 | — | — | US | claimed |
| EP-0220030-B1 | ORAL DELIVERY SYSTEM | BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) | 1991-06-19 | — | — | EP | claimed |
| EP-0267204-A4 | IMMUNOPOTENTIATION. | BIOENTPR PTY LTD (AU) | 1989-03-22 | — | — | EP | claimed |
| EP-0267204-A1 | IMMUNOPOTENTIATION. | BIOENTERPRISES PTY LTD (AU) | 1988-05-18 | — | — | EP | claimed |
| WO-1987006590-A1 | IMMUNOPOTENTIATION | BIOENTERPRISES PTY. LTD. (AU) | 1987-11-05 | — | — | WO | claimed |
| US-4665089-A | IMIDOESTER OR N-HYDROXYSUCCINIMIDE ESTER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1987-05-12 | — | — | US | claimed |
| EP-0199103-A2 | Process for preventing or reversing cataract formation using protein modification reagents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1986-10-29 | — | — | EP | claimed |
| US-4608246-A | Testing for a blood group immunological reaction | IMMUCOR, INC. (US) | 1986-08-26 | — | — | US | claimed |
| US-12622931-B2 | Compositions and methods for treating alpha-1 antitrypsin deficiency | BEAM THERAPEUTICS INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735015-A1 | HTT REPRESSORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116932-A1 | HTT REPRESSORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-30 | — | — | US | disclosed |
| US-12612618-B2 | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors | BEAM THERAPEUTICS INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108590-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108606-A1 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12600971-B2 | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | BEAM THERAPEUTICS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720081-A1 | CONJUGATE COMPOSITIONS COMPRISING PHOSPHORYL GUANIDINE LINKAGES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260091107-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-20260083861-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSION | EDITAS MEDICINE, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | VIRTUOSO BINCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12576151-B2 | Fratricide resistant modified immune cells and methods of using the same | BEAM THERAPEUTICS INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705346-A2 | ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF | Abilita Bio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570961-B2 | Methods and compositions for T-cell coculture potency assays and use with cell therapy products | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060996-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2026-03-05 | — | — | US | disclosed |
| US-20260061052-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-12553029-B2 | Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12553031-B2 | Methods and compositions for T-cell coculture potency assays and use with cell therapy products | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035693-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260021181-A1 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12529041-B2 | Compositions and methods for delivering a nucleobase editing system | BEAM THERAPEUTICS INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12521437-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20260007765-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | AVIDITY BIOSCIENCES, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | SOLVE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008990-A1 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260002159-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | EDITAS MEDICINE INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12497458-B2 | Anti-GAL3 antibodies and uses thereof | TRUEBINDING, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250376674-A1 | SPLIT PRIME EDITORS | PRIME MEDICINE INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | Synthorx, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4656242-A2 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12486328-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250352651-A1 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | Atrium Therapeutics, Inc. | 2025-11-20 | — | — | US | disclosed |
| EP-4126066-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340880-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333529-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12454694-B2 | Compositions and methods for improving base editing | BEAM THERAPEUTICS INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250325694-A1 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250329428-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3876973-B1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | SYNTHORX INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250319202-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY | PRIME MEDICINE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320491-A1 | CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | EDITAS MEDICINE, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-RE50631-E1 | ROR1 antibody immunoconjugates | VelosBio Inc. | 2025-10-14 | — | — | US | disclosed |
| US-12435120-B2 | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods | JUNO THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250302979-A1 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4623072-A2 | TWO-DIMENSIONAL PROCESSES FOR THE EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND THERAPIES THEREFROM | Iovance Biotherapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12427202-B2 | Compositions and methods of treating muscle dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250297287-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING THE NEONATAL FC RECEPTOR | APELLIS PHARMACEUTICALS, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250297248-A1 | METHODS AND COMPOSITIONS FOR INHIBITING MISMATCH REPAIR | PRIME MEDICINE, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-20250288690-A1 | RNA BASE EDITING COMPOSITIONS, SYSTEMS, METHODS AND USES THEREOF | BEAM THERAPEUTICS INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250288698-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | EDITAS MEDICINE, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250281537-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4612277-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD103 SELECTION | Iovance Biotherapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12409230-B2 | Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy | AVIDITY BIOSCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4608442-A1 | NUCLEIC ACID BASED VACCINE | GlaxoSmithKline Biologicals S.A. (BE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250262304-A1 | FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME | BEAM THERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12390523-B2 | Coronavirus vaccine | CureVac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20250250588-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250243282-A1 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TRUEBINDING, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250243474-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | PRIME MEDICINE, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4047092-B1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250236852-A1 | LARGE SERINE RECOMBINASES, SYSTEMS AND USES THEREOF | BEAM THERAPEUTICS INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4587560-A1 | LARGE SERINE RECOMBINASES, SYSTEMS AND USES THEREOF | Beam Therapeutics Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12364769-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12359202-B2 | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12351637-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250205352-A1 | COMPOSITIONS AND METHODS FOR MODULATING NaV1.8 | Atrium Therapeutics, Inc. | 2025-06-26 | — | — | US | disclosed |
| EP-3545963-B1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | SYNOVIS ORTHOPEDIC AND WOUNDCARE INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338436-B2 | Synthetic guide molecules, compositions and methods relating thereto | EDITAS MEDICINE, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250195676-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025122974-A1 | METHODS OF TREATING CANCER BY DETECTING GEN1 VARIATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12325854-B2 | Crispr-CPF1-related methods, compositions and components for cancer immunotherapy | EDITAS MEDICINE, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250177558-A1 | Functionalized Nanoclusters and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-20250179483-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1B | PRIME MEDICINE, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250179488-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4561636-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | Regeneron Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12318431-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250171544-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170260-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250161344-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4556489-A2 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Avidity Biosciences, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250152726-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250152699-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2025-05-15 | — | — | US | disclosed |
| US-20250154218-A1 | IL-2 Conjugates and Methods of Use to Treat Autoimmune Diseases | Synthorx, Inc. (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025101484-A1 | TREATMENT OF ENDOMETRIAL CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4551681-A1 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12297466-B2 | Engineered Cas9 nucleases | EDITAS MEDICINE, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250145722-A1 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE | TRUEBINDING, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-116478486-B | Anti-rust light high-strength plastic steel composite material and preparation method thereof | 深圳市高科塑化有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250127912-A1 | COMPOSITIONS FOR DELIVERY OF POLYNUCLEOTIDES | MIRECULE, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12281166-B2 | Methods of treating inflammatory diseases by blocking Galectin-3 | TRUEBINDING, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250121085-A1 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING | AVIDITY BIOSCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250108098-A1 | METHODS OF SUBSTITUTING PATHOGENIC AMINO ACIDS USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250108120-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2025-04-03 | — | — | US | disclosed |
| WO-2025072810-A1 | MITIGATION OF CHECKPOINT INHIBITOR-INDUCED AUTOIMMUNE HEMOLYTIC ANEMIA THROUGH MODULATION OF PURINERGIC SIGNALING | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12263224-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12264331-B2 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250099588-A1 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250101380-A1 | TUMOR INFILTRATING LYMPHOCYTES ENGINEERED TO EXPRESS PAYLOADS | IOVANCE BIOTHERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20250099623-A1 | COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION | THE BROAD INSTITUTE, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250092450-A1 | IDENTIFICATION OF NANOPARTICLES FOR PREFERENTIAL TISSUE OR CELL TARGETING | BEAM THERAPEUTICS INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250092146-A1 | ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF | ABILITA BIO, INC. D/B/A ABILITA THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025054540-A1 | METHODS OF GENE-EDITING USING PROGRAMMABLE NUCLEASES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250073352-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | PRIME MEDICINE, INC. | 2025-03-06 | — | — | US | disclosed |
| EP-4516358-A2 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12234271-B2 | Il-2 conjugates and methods of use to treat autoimmune diseases | Synthorx, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12234290-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12230379-B2 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12230378-B2 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250051474-A1 | ANTI-CD97 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4504220-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Iovance Biotherapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4499679-A2 | COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION | The Broad Institute, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12214055-B2 | Systems and methods for treating hyper-igm syndrome | EDITAS MEDICINE INC. | 2025-02-04 | — | — | US | disclosed |
| US-20250032622-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| US-20250032618-A1 | METHODS OF EXPANSION TREATMENT UTILIZING CD8 TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119365597-A | Antibody oligonucleotide conjugate compositions and methods for inducing DMD exon 44 skipping | 艾维迪提生物科学公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250025569-A1 | TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACE | MIRECULE INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250025573-A1 | NOVEL RNA BASE EDITING COMPOSITIONS, SYSTEMS, METHODS AND USES THEREOF | BEAM THERAPEUTICS INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250026838-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TRUEBINDING, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-4495235-A2 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | Editas Medicine, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201699-B2 | Compositions and methods for promoting homology directed repair | EDITAS MEDICINE, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20250017971-A1 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | GRAF FINCK VON FINCKENSTEIN, FRIEDRICH-REINHARD | 2025-01-16 | — | — | US | disclosed |
| EP-4491229-A2 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTALMIC DISEASES | CureVac SE (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-12194089-B2 | Coronavirus vaccine | CureVac SE (DE) | 2025-01-14 | — | — | US | disclosed |
| US-20250011766-A1 | Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis | PRIME MEDICINE, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4486394-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12186389-B2 | Nucleic acid base vaccine against emerging SARS-CoV-2 variants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-01-07 | — | — | US | disclosed |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| WO-2025004001-A1 | HTT REPRESSORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-02 | — | — | WO | disclosed |
| US-20240424097-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1 TALEN KNOCKDOWN | IOVANCE BIOTHERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-119162273-A | Boron-containing composition for preparing lactulose, preparation method and application thereof | 中国科学院天津工业生物技术研究所 | 2024-12-20 | — | — | CN | disclosed |
| CN-119162267-A | Boron-containing composition, preparation method and application thereof | 中国科学院天津工业生物技术研究所 | 2024-12-20 | — | — | CN | disclosed |
| US-20240417706-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-12170134-B2 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240408136-A1 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240412835-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240400707-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240398989-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS | THE BROAD INSTITUTE, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024249944-A1 | CONJUGATE COMPOSITIONS COMPRISING PHOSPHORYL GUANIDINE LINKAGES AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12157774-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12159700-B2 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240390424-A1 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4464338-A2 | SYSTEMS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | Editas Medicine, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240376468-A1 | CIRCULAR GUIDE RNAs FOR CRISPR/CAS EDITING SYSTEMS | BEAM THERAPEUTICS INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240368598-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | AVIDITY BIOSCIENCES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240365776-A1 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240368543-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | GRAF FINCK VON FINCKENSTEIN, FRIEDRICH-REINHARD | 2024-11-07 | — | — | US | disclosed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240366680-A1 | TREATMENT OF PAIN | EDITAS MEDICINE, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-3758729-B1 | IL-15 CONJUGATES AND USES THEREOF | SYNTHORX INC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12133884-B2 | Methods of substituting pathogenic amino acids using programmable base editor systems | BEAM THERAPEUTICS INC. (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024226838-A2 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240358736-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240360433-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) | BEAM THERAPEUTICS INC. (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024227083-A2 | ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF | Abilita Bio, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240360471-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING BETA HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4452333-A1 | CROSSLINKING ANTIBODIES | Enlaza Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240352453-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY | PRIME MEDICINE, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-4448000-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) | Beam Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240342285-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240335476-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240335516-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) | BEAM THERAPEUTICS INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240325446-A1 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | GRAF FINCK VON FINCKENSTEIN, FRIEDRICH-REINHARD | 2024-10-03 | — | — | US | disclosed |
| US-20240325533-A1 | MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME | BEAM THERAPEUTICS INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240327813-A1 | CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | BEAM THERAPEUTICS INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240325509-A1 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12104156-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118662652-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118667812-A | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307437-A1 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240309382-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-09-19 | — | — | US | disclosed |
| WO-2024191972-A2 | ANTI-LIPOCALIN-2 ANTIBODIES AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-3443088-B1 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE INC (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118638788-A | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118638787-A | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240299540-A1 | ADJUVANT THERAPY FOR CANCER | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240299539-A1 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240301419-A1 | UNA AMIDITES AND USES THEREOF | Atrium Therapeutics, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240301405-A1 | GUIDE RNAS FOR CRISPR/CAS EDITING SYSTEMS | BEAM THERAPEUTICS INC. | 2024-09-12 | — | — | US | disclosed |
| EP-3701028-B1 | SYSTEMS AND METHODS FOR TREATING HYPER-IGM SYNDROME | EDITAS MEDICINE INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118619860-A | Purification process of N, N '-dimethyl-3, 3' -dithiodipropionamide | 山东裕滨新材料有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240293519-A1 | Universal mRNA Vaccine to Treat Dementia-Causing Neurodegenerative Disorders | RNA Therapeutics, Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240294914-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | BEAM THERAPEUTICS INC. (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4423755-A2 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287522-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240287453-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | BEAM THERAPEUTICS INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2024-08-29 | — | — | US | disclosed |
| US-12071621-B2 | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping | AVIDITY BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-12071485-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118541159-A | Methods of producing TIL products using PD-1 TALEN gene knockdown | 艾欧凡斯生物治疗公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240277830-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-08-22 | — | — | US | disclosed |
| US-12064483-B2 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | AVIDITY BIOSCIENCES, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240269180-A1 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4408986-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | Beam Therapeutics Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240252543-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR IMPROVING TRANSPLANTATION | EDITAS MEDICINE, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240252550-A1 | GENETIC MODIFICATION OF HEPATOCYTES | BEAM THERAPEUTICS INC. | 2024-08-01 | — | — | US | disclosed |
| US-12049651-B2 | Cas9 fusion molecules, gene editing systems, and methods of use thereof | EDITAS MEDICINE, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-12049629-B2 | Compositions and methods of treating Facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229038-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE | PRIME MEDICINE, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228988-A1 | COMPOSITIONS AND METHODS FOR EFFICIENT GENOME EDITING | PRIME MEDICINE, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240229075-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148313-A2 | GENOME EDITING COMPOSITIONS AND METHODS OF USE | PRIME MEDICINE, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12031132-B2 | Systems and methods for the treatment of hemoglobinopathies | EDITAS MEDICINE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-111902148-B | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267396-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118265544-A | Compositions and methods for treating facial shoulder brachial muscular dystrophy | 艾维迪提生物科学公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240207318-A1 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | ZHANG YONGLIANG (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207448-A1 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | EDITAS MEDICINE, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4388105-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | Beam Therapeutics Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12016908-B2 | Compositions and methods for treating hemoglobinopathies | BEAM THERAPEUTICS INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240191197-A1 | MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2024118836-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES WITH SHORTENED REP STEP | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182561-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4377446-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024112571-A2 | TWO-DIMENSIONAL PROCESSES FOR THE EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND THERAPIES THEREFROM | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240173426-A1 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4373270-A2 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | Iovance Biotherapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240167008-A1 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | BEAM THERAPEUTICS INC. (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024107765-A2 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240167026-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE | PRIME MEDICINE, INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240167059-A1 | SYSTEMS AND METHODS FOR TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF USING INTEGRATED PRIMING SITES | EDITAS MEDICINE, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158775-A1 | ADENOSINE DEAMINASE VARIANTS AND USES THEREOF | BEAM THERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240158512-A1 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | TRUEBINDING, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156949-A1 | Nucleic Acid Based Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-05-16 | — | — | US | disclosed |
| US-20240156946-A1 | RNA VACCINE AGAINST SARS-COV-2 VARIANTS | CureVac SE (DE) | 2024-05-16 | — | — | US | disclosed |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| WO-2024098002-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024098027-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD103 SELECTION | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| EP-3215617-B1 | SYSTEMS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE INC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024089638-A1 | NUCLEIC ACID BASED VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-05-02 | — | — | WO | disclosed |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240132868-A1 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | BEAM THERAPEUTICS INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240133871-A1 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2024-04-25 | — | — | US | disclosed |
| US-20240132867-A1 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11964011-B2 | Coronavirus vaccine | CureVac SE (DE) | 2024-04-23 | — | — | US | disclosed |
| US-11964012-B2 | Coronavirus vaccine | CureVac SE (DE) | 2024-04-23 | — | — | US | disclosed |
| US-11963982-B2 | CRISPR/RNA-guided nuclease systems and methods | EDITAS MEDICINE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240123067-A1 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4352105-A2 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TrueBinding, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240117345-A1 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | BEAM THERAPEUTICS INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4346840-A2 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | Beam Therapeutics Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240110152-A1 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240102065-A1 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CureVac SE (DE) | 2024-03-28 | — | — | US | disclosed |
| EP-4340850-A1 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-111655268-B | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024059791-A1 | LARGE SERINE RECOMBINASES, SYSTEMS AND USES THEREOF | BEAM THERAPEUTICS INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4337246-A2 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | Beam Therapeutics Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240082375-A1 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | IOVANCE BIOTHERAPEUTICS, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4334446-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-11919934-B2 | IL-15 conjugates and uses thereof | Synthorx, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11918643-B2 | RNA vaccine against SARS-CoV-2 variants | CureVac SE (DE) | 2024-03-05 | — | — | US | disclosed |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | EDITAS MEDICINE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024044636-A2 | NANOCLUSTERS FUNCTIONALIZED WITH ADENOSINE TRIPHOSPHATE OR AN ANALOGUE AND THEIR USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240067940-A1 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | PRIME MEDICINE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066114-A1 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CureVac SE (DE) | 2024-02-29 | — | — | US | disclosed |
| EP-4326287-A2 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | Iovance Biotherapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | EDITAS MEDICINE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024030758-A1 | CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4314253-A2 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | Iovance Biotherapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4314265-A2 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | Beam Therapeutics Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026474-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11883486-B2 | — | — | 2024-01-30 | — | — | US | disclosed |
| US-11872280-B2 | RNA vaccine against SARS-CoV-2 variants | CureVac SE (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11872287-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024011114-A1 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240011007-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | PRIME MEDICINE, INC. | 2024-01-11 | — | — | US | disclosed |
| US-11866726-B2 | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites | EDITAS MEDICINE, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3363903-B1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | EDITAS MEDICINE INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230416787-A1 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | EDITAS MEDICINE, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11851690-B2 | Systems and methods for the treatment of hemoglobinopathies | EDITAS MEDICINE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230398231-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-4288140-A1 | ADJUVANT THERAPY FOR CANCER | Iovance Biotherapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4284919-A1 | METHODS OF MAKING MODIFIED TUMOR INFILTRATING LYMPHOCYTES AND THEIR USE IN ADOPTIVE CELL THERAPY | Iovance Biotherapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834649-B2 | CRISPR/CAS-related methods and compositions for treating herpes simplex virus | EDITAS MEDICINE, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834510-B2 | Anti-transferrin receptor antibodies and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230383277-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230372397-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374453-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230364223-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365980-A1 | METHODS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364256-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 44 SKIPPING | AVIDITY BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220608-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4271791-A2 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4267178-A1 | RNA VACCINE AGAINST SARS-COV-2 VARIANTS | CureVac SE (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-20230340456-A1 | USE OF EXONUCLEASES TO IMPROVE CRISPR/CAS-MEDIATED GENOME EDITING | EDITAS MEDICINE, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230340474-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4262827-A1 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4262811-A1 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330246-A1 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | AVIDITY BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4259164-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH BRAF INHIBITORS AND/OR MEK INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023196877-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230302089-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302122-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183906-A2 | COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION | THE BROAD INSTITUTE, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293685-A1 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | IOVANCE BIOTHERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293672-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230287420-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11752202-B2 | Compositions and methods for treating hemoglobinopathies | BEAM THERAPEUTICS INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-110036028-B | anti-IL 1-RAP antibodies | 坎塔吉亚有限责任公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230279373-A1 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | BEAM THERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279395-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279120-A1 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | TRUEBINDING, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023164224-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230272052-A1 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CureVac SE (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4225330-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Iovance Biotherapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225331-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Iovance Biotherapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230241002-A1 | METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS | MODERNATX, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023147486-A1 | TUMOR INFILTRATING LYMPHOCYTES ENGINEERED TO EXPRESS PAYLOADS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147488-A1 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230242884-A1 | COMPOSITIONS AND METHODS FOR ENGRAFTMENT OF BASE EDITED CELLS | BEAM THERAPEUTICS INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4216972-A1 | FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME | Beam Therapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11712478-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-113651769-B | Continuous production method of 2-methyl-4-isothiazolin-3-ketone | 陕西中杰科仪化学科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| EP-4215543-A2 | HPV-SPECIFIC BINDING MOLECULES | Juno Therapeutics, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11707532-B2 | Compositions and methods of treating muscle dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701407-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023133522-A2 | TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACE | MIRECULE, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11692205-B2 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230201363-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023122753-A1 | CROSSLINKING ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122347-A2 | COMPOSITIONS FOR DELIVERY OF POLYNUCLEOTIDES | MIRECULE, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201362-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-116322758-A | Nucleic acid-based combination vaccine | 库尔维科欧洲股份公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023115012-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) | BEAM THERAPEUTICS INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11680268-B2 | Methods for improving CRISPR/Cas-mediated genome-editing | EDITAS MEDICINE, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230187042-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230172987-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11667911-B2 | Use of exonucleases to improve CRISPR/CAS-mediated genome editing | EDITAS MEDICINE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230159956-A1 | METHODS OF EDITING SINGLE NUCLEOTIDE POLYMORPHISM USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023086768-A1 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | TRUEBINDING, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086803-A1 | METHODS OF EXPANSION TREATMENT UTILIZING CD8 TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149561-A1 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| US-20230140953-A1 | METHODS OF EDITING A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | BEAM THERAPEUTICS INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023077015-A2 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230137729-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | JUNO THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4172194-A1 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CureVac SE (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128472-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11631483-B2 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230111575-A1 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | EDITAS MEDICINE, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11622993-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4157344-A2 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CureVac SE (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157338-A2 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TrueBinding, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230094463-A1 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TRUEBINDING, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023049935-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | BEAM THERAPEUTICS INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230101597-A1 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | BEAM THERAPEUTICS INC. (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023049862-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-115838346-A | Method for synthesizing N, N '-dialkyl-3, 3' -dithiodipropionamide by one-pot method | 大连百傲化学股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230091801-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2023043953-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-115806532-A | Preparation method of impurities in MIT | 大连百傲化学股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20230080198-A1 | MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-4146229-A1 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | Avidity Biosciences, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4147717-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146794-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146793-A1 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | Iovance Biotherapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230075877-A1 | NOVEL NUCLEOBASE EDITORS AND METHODS OF USING SAME | BEAM THERAPEUTICS INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230070861-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | BEAM THERAPEUTICS INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11596686-B2 | Coronavirus vaccine | CureVac SE (DE) | 2023-03-07 | — | — | US | disclosed |
| US-11597924-B2 | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use | EDITAS MEDICINE, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230061455-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY | JUNO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4139440-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023023515-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | BEAM THERAPEUTICS INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230059368-A1 | POLYNUCLEOTIDE EDITORS AND METHODS OF USING THE SAME | PRIME MEDICINE, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055682-A1 | SYNTHETIC GUIDE RNA, COMPOSITIONS, METHODS, AND USES THEREOF | BEAM THERAPEUTICS INC. | 2023-02-23 | — | — | US | disclosed |
| US-11583591-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230047754-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11576966-B2 | Coronavirus vaccine | CureVac SE (DE) | 2023-02-14 | — | — | US | disclosed |
| US-11576980-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230038993-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | EDITAS MEDICINE, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2023009716-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH KRAS INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230036181-A1 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE | TRUEBINDING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11564893-B2 | Methods for preparing particles and related compositions | MODERNATX, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023004074-A2 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230026726-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | EDITAS MEDICINE, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230025279-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230021636-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LIQUID CANCERS | BEAM THERAPEUTICS INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4123024-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | Editas Medicine, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230018543-A1 | CRISPR/CAS-MEDIATED GENE CONVERSION | EDITAS MEDICINE, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230017979-A1 | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING | BEAM THERAPEUTICS INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11555190-B2 | Compositions and methods of treating Facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2022245754-A9 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20230002760-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | EDITAS MEDICINE, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220411514-A1 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TRUEBINDING, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220409735-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220401530-A1 | METHODS OF SUBSTITUTING PATHOGENIC AMINO ACIDS USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2022-12-22 | — | — | US | disclosed |
| EP-3129485-B2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395580-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395570-A1 | CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2022-12-15 | — | — | US | disclosed |
| WO-2022261113-A2 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TRUEBINDING, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11525137-B2 | Compositions and methods of treating Facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220389460-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387622-A1 | METHODS OF EDITING A SINGLE NUCLEOTIDE POLYMORPHISM USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220380473-A1 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | TRUEBINDING, INC. | 2022-12-01 | — | — | US | disclosed |
| WO-2022251687-A2 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | BEAM THERAPEUTICS INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11512311-B2 | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency | EDITAS MEDICINE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220370575-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022245754-A1 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022241270-A2 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | BEAM THERAPEUTICS INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4087938-A2 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CureVac AG (DE) | 2022-11-16 | — | — | EP | disclosed |
| US-11497814-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-11499151-B2 | Methods and systems for analyzing guide RNA molecules | EDITAS MEDICINE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220348908-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION | FLAGSHIP LABS 114, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220339293-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| US-20220331422-A1 | RNA vaccine against SARS-CoV-2 variants | CUREVAC AG (DE) | 2022-10-20 | — | — | US | disclosed |
| US-11471525-B2 | Coronavirus vaccine | CUREVAC AG (DE) | 2022-10-18 | — | — | US | disclosed |
| US-20220324984-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220325326-A1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | EDITAS MEDICINE, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220313799-A1 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | BEAM THERAPEUTICS INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220313833-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220313806-A1 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | IOVANCE BIOTHERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220313813-A1 | ROTAVIRUS MRNA VACCINE | CUREVAC AG (DE) | 2022-10-06 | — | — | US | disclosed |
| WO-2022204564-A2 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| US-11446387-B2 | Compositions and methods of treating muscle dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4054644-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220273767-A1 | Interleukin 10 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2022-09-01 | — | — | US | disclosed |
| US-11427638-B2 | Anti-Gal3 antibodies and uses thereof | TRUEBINDING, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220265763-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4047092-A1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | Editas Medicine, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022170219-A1 | ADJUVANT THERAPY FOR CANCER | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220249654-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2022-08-11 | — | — | US | disclosed |
| WO-2022162027-A2 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CUREVAC AG (DE) | 2022-08-04 | — | — | WO | disclosed |
| US-11400163-B2 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | AVIDITY BIOSCIENCES, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220235347-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2022-07-28 | — | — | US | disclosed |
| US-20220227855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS | 2022-07-21 | — | — | US | disclosed |
| EP-3386520-B1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | UNIV CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11390861-B2 | CRISPR/cas-related methods and compositions for treating herpes simplex virus | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11390887-B2 | CRISPR-related methods and compositions with governing gRNAS | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220218815-A1 | CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2022-07-14 | — | — | US | disclosed |
| US-20220211838-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2022-07-07 | — | — | US | disclosed |
| WO-2022147196-A2 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220211841-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2022-07-07 | — | — | US | disclosed |
| WO-2022137133-A1 | RNA VACCINE AGAINST SARS-COV-2 VARIANTS | CUREVAC AG (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220202930-A1 | RNA vaccine against SARS-CoV-2 variants | CUREVAC AG (DE) | 2022-06-30 | — | — | US | disclosed |
| EP-4019635-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | Editas Medicine, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019975-A1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | Editas Medicine, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220193226-A1 | CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2022-06-23 | — | — | US | disclosed |
| WO-2022133149-A1 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133140-A1 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-11364302-B1 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022125941-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH BRAF INHIBITORS AND/OR MEK INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220184131-A1 | CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | JUNO THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220186199-A1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220177861-A1 | ENGINEERED CAS9 NUCLEASES | EDITAS MEDICINE, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220170027-A1 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11344609-B2 | Compositions and methods for treating hemoglobinopathies | BEAM THERAPEUTICS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11339437-B2 | Compositions and methods for treating CEP290-associated disease | EDITAS MEDICINE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3996751-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220145316-A1 | CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-12 | — | — | US | disclosed |
| US-20220144943-A1 | ANTI-CD47 ANTIBODIES AND USES THEREOF | INTEGRITY BIOVENTURES, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3993828-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CureVac AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| US-20220133908-A1 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | CUREVAC AG (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135970-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133901-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | VelosBio Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133768-A1 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | EDITAS MEDICINE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220136012-A1 | NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133790-A1 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE | BEAM THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133900-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220127622-A1 | Compositions and Methods for Improving Base Editing | BEAM THERAPEUTICS INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127594-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3986452-A1 | ROTAVIRUS MRNA VACCINE | CureVac AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-11311627-B1 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | AVIDITY BIOSCIENCES LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220122707-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022076606-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076952-A1 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106600-A1 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | EDITAS MEDICINE, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11291707-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-05 | — | — | US | disclosed |
| US-11293868-B2 | Ratiometric fluorescence imaging methods | AVELAS BIOSCIENCES, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220098572-A1 | NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS | BEAM THERAPEUTICS INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220098593-A1 | SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | BEAM THERAPEUTICS INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022067089-A1 | FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME | BEAM THERAPEUTICS INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220096647-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-20220088213-A1 | DRUG DELIVERY SYSTEM USING PH-DEPENDENT CELL-PENETRATING PEPTIDES, AND COMPOSITE THEREOF WITH DRUG | KIM SUNG CHUN (KR) | 2022-03-24 | — | — | US | disclosed |
| US-20220089768-A1 | MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF | TRIO PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220073951-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220072145-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220072160-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | EDITAS MEDICINE, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220062434-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022043551-A2 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CUREVAC AG (DE) | 2022-03-03 | — | — | WO | disclosed |
| US-20220059202-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3957735-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | Editas Medicine, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11253607-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220047637-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-11246941-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11242525-B2 | CRISPR/CAS-related methods and compositions for treating sickle cell disease | EDITAS MEDICINE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241493-B2 | Coronavirus vaccine | CUREVAC AG (DE) | 2022-02-08 | — | — | US | disclosed |
| WO-2022023559-A1 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CUREVAC AG (DE) | 2022-02-03 | — | — | WO | disclosed |
| US-11236313-B2 | Cas9 fusion molecules, gene editing systems, and methods of use thereof | EDITAS MEDICINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220025363-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220017927-A1 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | EDITAS MEDICINE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220016249-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220008550-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2021239880-A9 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-20220010313-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | EDITAS MEDICINE, INC. (US) | 2022-01-13 | — | — | US | disclosed |
| US-20220002420-A1 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | TRUEBINDING, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20220002432-A1 | CD38 AND ICAM1 ANTIBODIES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| US-20210407639-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20210407640-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3924478-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | Beam Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924480-A1 | MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE | Beam Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3920950-A1 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTALMIC DISEASES | CureVac AG (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210380955-A1 | METHODS OF EDITING SINGLE NUCLEOTIDE POLYMORPHISM USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380680-A1 | ANTI-CLAUDIN ANTIBODIES AND USES THEREOF | ZLIP HOLDING LIMITED (KY) | 2021-12-09 | — | — | US | disclosed |
| US-20210379181-A1 | CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210380987-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3918077-A1 | NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE | Beam Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3918078-A1 | NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS | Beam Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021242776-A2 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TRUEBINDING, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021239880-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2021-12-02 | — | — | WO | disclosed |
| US-20210371858-A1 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210369762-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371533-A1 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TRUEBINDING, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210363522-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS TARGETING VIRUS GENOMES | EDITAS MEDICINE, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3443086-B1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911735-A2 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE | Beam Therapeutics, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11179472-B2 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | AVIDITY BIOSCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180793-B2 | Evaluation of Cas9 molecule/guide RNA molecule complexes | EDITAS MEDICINE, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021226085-A1 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226107-A1 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | AVIDITY BIOSCIENCES, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226061-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3906055-A2 | MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF | Trio Pharmaceuticals, Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2021216920-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210335467-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2021-10-28 | — | — | US | disclosed |
| EP-3898693-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897702-A2 | RNA FOR MALARIA VACCINES | CureVac AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-11155803-B2 | Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence | BEAM THERAPEUTICS INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11141493-B2 | Compositions and methods for treating CEP290-associated disease | EDITAS MEDICINE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142760-B2 | Compositions and methods for treating hemoglobinopathies | BEAM THERAPEUTICS INC. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3886897-A1 | CORONAVIRUS VACCINE | CureVac AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210301274-A1 | Compositions and Methods for Delivering a Nucleobase Editing System | BEAM THERAPEUTICS INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210301290-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210284709-A1 | HPV-SPECIFIC BINDING MOLECULES | JUNO THERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210277379-A1 | MULTI-EFFECTOR NUCLEOBASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEIC ACID TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3876196-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | Avelas Biosciences, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-11110180-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210252118-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | BEAM THERAPEUTICS INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210254061-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2021-08-19 | — | — | US | disclosed |
| EP-3864030-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | The Scripps Research Institute (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3286571-B1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | EDITAS MEDICINE INC (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021156267-A1 | CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2021-08-12 | — | — | WO | disclosed |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210230638-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3114227-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3851530-A1 | CRISPR/CAS-MEDIATED GENE CONVERSION | Editas Medicine, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3847254-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM | Beam Therapeutics Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210187116-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210179720-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11028394-B2 | CRISPR/CAS-related methods and compositions for treating cystic fibrosis | EDITAS MEDICINE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028411-B2 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028179-B2 | Anti-transferrin receptor antibodies and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028388-B2 | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11001844-B2 | CRISPR/Cas-related methods and compositions for treating herpes simplex virus | EDITAS MEDICINE, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210130805-A1 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130486-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| EP-3122880-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | EDITAS MEDICINE INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10994017-B2 | Nerve labeling compositions and uses thereof | AVELAS BIOSCIENCES, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10994020-B2 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | AVIDITY BIOSCIENCES, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20210115475-A1 | SYSTEMS AND METHODS FOR MODULATING CHROMOSOMAL REARRANGEMENTS | EDITAS MEDICINE, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210113702-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| US-20210113655-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| EP-3800248-A2 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | Editas Medicine, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210095283-A1 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | Atrium Therapeutics, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-20210085785-A1 | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER | IMMUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3786294-A1 | USE OF EXONUCLEASES TO IMPROVE CRISPR/CAS-MEDIATED GENOME EDITING | Editas Medicine, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2021028439-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2021-02-18 | — | — | WO | disclosed |
| US-20210040506-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS | EDITAS MEDICINE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10913800-B2 | Anti-transferrin receptor antibodies and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3274453-B1 | CRISPR/CAS-MEDIATED GENE CONVERSION | EDITAS MEDICINE INC (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2021011398-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3758729-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10881743-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200405877-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| EP-3755350-A1 | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER | TRUEBINDING, INC. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200399338-A1 | IL-15 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020254535-A1 | ROTAVIRUS MRNA VACCINE | CUREVAC AG (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392208-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS (HSV) RELATED KERATITIS | EDITAS MEDICINE, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| EP-3748004-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND BECKER MUSCULAR DYSTROPHY | Editas Medicine, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3735252-A2 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3353296-B1 | USE OF EXONUCLEASES TO IMPROVE CRISPR/CAS-MEDIATED GENOME EDITING | EDITAS MEDICINE INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200338210-A1 | ANTI-ROR1 ANTIBODY AND CONJUGATES THEREOF | ARDEAGEN CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-20200338213-A1 | SYSTEMS AND METHODS FOR TREATING HYPER-IGM SYNDROME | EDITAS MEDICINE INC. | 2020-10-29 | — | — | US | disclosed |
| WO-2020219497-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200325237-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-10-15 | — | — | US | disclosed |
| EP-3720448-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | Avidity Biosciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10800848-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200315967-A1 | LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200308604-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10787519-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200299661-A1 | CPF1-RELATED METHODS AND COMPOSITIONS FOR GENE EDITING | EDITAS MEDICINE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200282074-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10765759-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3132030-B1 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | EDITAS MEDICINE INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200263206-A1 | TARGETED INTEGRATION SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| WO-2020168088-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168122-A1 | MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020150534-A9 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE | BEAM THERAPEUTICS INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020161342-A1 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTALMIC DISEASES | CUREVAC AG (DE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200255857-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING BETA HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2020-08-13 | — | — | US | disclosed |
| EP-3691657-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10736989-B2 | Methods and compositions for stabilizing the myocardium | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | SYNTHORX INC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2020160517-A1 | NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE | BEAM THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160514-A1 | NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS | BEAM THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3684376-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Avidity Biosciences, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020150534-A2 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE | BEAM THERAPEUTICS INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231644-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SANOFI (FR) | 2020-07-23 | — | — | US | disclosed |
| WO-2020142659-A2 | MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF | TRIO PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216843-A1 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | EDITAS MEDICINE, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2020132584-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128031-A2 | RNA FOR MALARIA VACCINES | CUREVAC AG (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2020-06-18 | — | — | US | disclosed |
| US-20200190513-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | EDITAS MEDICINE, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190105-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | THE SCRIPPS RESEARCH INSTITUTE | 2020-06-18 | — | — | US | disclosed |
| EP-3277816-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND BECKER MUSCULAR DYSTROPHY | EDITAS MEDICINE INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SYNTHORX INC (US) | 2020-06-11 | — | — | US | disclosed |
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661955-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661956-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165636-A1 | SYSTEMS AND METHODS FOR TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF USING INTEGRATED PRIMING SITES | EDITAS MEDICINE, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155606-A1 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | EDITAS MEDICINE, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157515-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200150041-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | AVELAS ACQUISITION CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-10640788-B2 | CRISPR-related methods and compositions with governing gRNAs | EDITAS MEDICINE, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3641830-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | Velosbio Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123261-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC | 2020-04-23 | — | — | US | disclosed |
| US-10610571-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20200085910-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-03-19 | — | — | US | disclosed |
| EP-3622070-A2 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | Editas Medicine, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3615672-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | Editas Medicine, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | AVELAS ACQUISITION CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20200056208-A1 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | EDITAS MEDICINE, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| US-20200056164-A1 | ENGINEERED CAS9 NUCLEASES | EDITAS MEDICINE, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-3610243-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | Avelas Biosciences, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10550188-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20200030454-A1 | ROR1 Antibody Immunoconjugates | VelosBio Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200017849-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE, INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190345490-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3565577-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Avidity Biosciences LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3556858-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | Editas Medicine, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2019-10-17 | — | — | US | disclosed |
| EP-3553176-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | Editas Medicine, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3548097-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | Avelas Biosciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190298847-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-3545963-A1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | Synovis Orthopedic and Woundcare, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10428319-B2 | Engineered Cas9 nucleases | EDITAS MEDICINE, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3540061-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA | Editas Medicine, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019165233-A1 | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER | IMMUTICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165453-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190249157-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | EDITAS MEDICINE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2001521-B1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | SYNOVIS ORTHOPEDIC AND WOUNDCARE INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10350267-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2019136180-A2 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190201550-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | EDITAS MEDICINE, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10335496-B2 | ROR1 antibody immunoconjugates | VelosBio Inc. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190192681-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3498845-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | Editas Medicine, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2019113393-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-3129485-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169639-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190142971-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3116997-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190136230-A1 | GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME | JUNO THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190136210-A1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | MODERNATX, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| WO-2019071028-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2019-04-11 | — | — | WO | disclosed |
| US-10253312-B2 | CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) | EDITAS MEDICINE, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2019060775-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES LLC (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20190054112-A1 | POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES | MODERNATX, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190048337-A1 | Crispr/Cas-Related Methods and Compositions for Treating Duchenne Muscular Dystrophy and Becker | EDITAS MEDICINE, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2019028425-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3436588-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10190137-B2 | CRISPR-related methods and compositions with governing gRNAS | EDITAS MEDICINE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190000986-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190000987-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20180371102-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180369400-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180369406-A1 | ROR1 Antibody Immunoconjugates | VelosBio Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018237335-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | VelosBio Inc. (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180355332-A1 | ENGINEERED CAS9 NUCLEASES | EDITAS MEDICINE, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3126497-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | EDITAS MEDICINE INC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018209158-A2 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | EDITAS MEDICINE, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180325999-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-15 | — | — | US | disclosed |
| US-20180318431-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-08 | — | — | US | disclosed |
| WO-2018201086-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | EDITAS MEDICINE, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180296603-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR IMPROVING TRANSPLANTATION | EDITAS MEDICINE, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180298392-A1 | METHODS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3386520-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | The Regents of The University of California (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018187629-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | AVELAS BIOSCIENCES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| US-20180282762-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20180273932-A1 | USE OF EXONUCLEASES TO IMPROVE CRISPR/CAS-MEDIATED GENOME EDITING | EDITAS MEDICINE, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20180251792-A1 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | EDITAS MEDICINE, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180251770-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | EDITAS MEDICINE, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180250424-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | EDITAS MEDICINE, INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180243230-A1 | METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS | MODERNATX, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180236103-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS | EDITAS MEDICINE, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3363903-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180214579-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180201956-A1 | SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA | EDITAS MEDICINE, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180195058-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018129384-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES LLC (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018119314-A1 | ANTI-ROR1 ANTIBODY AND CONJUGATES THEREOF | ARDEAGEN CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-10006054-B1 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180155789-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | EDITAS MEDICINE, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018102762-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | AVELAS BIOSCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180135109-A1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | EDITAS MEDICINE, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180127783-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9963719-B1 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180119123-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS | EDITAS MEDICINE, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180112213-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | EDITAS MEDICINE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2018067461-A1 | VIRAL DISK ASSEMBLIES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-12 | — | — | WO | disclosed |
| US-9938521-B2 | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) | EDITAS MEDICINE, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9925277-B2 | Polynucleotide compositions containing amino acids | MODERNATX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925237-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3066201-B1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | EDITAS MEDICINE INC (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2018018010-A1 | FGF MUTANTS AND USES THEREOF | METACRINE, INC. (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017223135-A1 | LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-2336161-B1 | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. | ABBVIE DEUTSCHLAND (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9834791-B2 | CRISPR-related methods and compositions with governing gRNAS | EDITAS MEDICINE, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170314015-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | EDITAS MEDICINE, INC. | 2017-11-02 | — | — | US | disclosed |
| EP-3233132-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2268673-B1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170281795-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| WO-2017173408-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-2338333-B1 | Glycopegylation methods and proteins/peptides produced by the methods | RATIOPHARM GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNATX, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9694037-B2 | Stabilized, sterilized collagen scaffolds with active adjuncts attached | SYNOVIS ORTHOPEDIC AND WOUNDCARE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170175128-A1 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | EDITAS MEDICINE, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2017100470-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3177732-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | ModernaTX, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170119925-A1 | METHODS AND COMPOSITIONS FOR STABILIZING THE MYOCARDIUM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-04 | — | — | US | disclosed |
| US-20170112899-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-27 | — | — | US | disclosed |
| WO-2017049074-A1 | POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073685-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | EDITAS MEDICINE, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073674-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE, INC. | 2017-03-16 | — | — | US | disclosed |
| WO-2017031232-A1 | METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS | MODERNATX, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-3129485-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | Editas Medicine, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029850-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA | EDITAS MEDICINE, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-3122880-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | Editas Medicine, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20170022507-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-3116997-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | Editas Medicine, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20170007679-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS | EDITAS MEDICINE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| EP-3114227-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | Editas Medicine, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2322229-B1 | Remodeling and glycoconjugation of Factor IX | NOVO NORDISK AS (DK) | 2016-12-21 | — | — | EP | disclosed |
| US-9513289-B2 | Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases | The United Sates of America, as Represented by the Department of Veterans Affairs (US) | 2016-12-06 | — | — | US | disclosed |
| US-9513288-B2 | Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160281111-A1 | CRISPR/CAS-MEDIATED GENE CONVERSION | EDITAS MEDICINE, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3066201-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | Editas Medicine, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9428561-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160243259-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| US-20160237455-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS | EDITAS MEDICINE, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9415135-B2 | Methods and compositions for stabilizing the myocardium | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| WO-2016100812-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9272004-B2 | Stabilized, sterilized collagen scaffolds with active adjuncts attached | SYNOVIS ORTHOPEDIC AND WOUNDCARE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2016022914-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2016-02-11 | — | — | US | disclosed |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY SCIENCE TECH & RES (SG) | 2016-01-21 | — | — | US | disclosed |
| EP-1594891-B1 | AMYLOID-BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF, ANTIBODIES FOR THE SAME, METHOD FOR PRODUCTION AND USE THEROF | ABBVIE DEUTSCHLAND (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2305314-B1 | Remodelling and glycoconjugation of antibodies | RATIOPHARM GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| EP-1765853-B1 | O-linked glycosylation of G-CSF peptides | RATIOPHARM GMBH (DE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015157070-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150274847-A1 | ANTIBODY TOXIN CONJUGATES | NOVO NORDISK AS (DK) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148863-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | EDITAS MEDICINE, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015138510-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE., INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-2279753-B1 | Remodeling and glycoconjugation of peptides | NOVO NORDISK AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015134812-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252358-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150232881-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2015070083-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE,INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150119332-A1 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-9005625-B2 | Antibody toxin conjugates | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| EP-2305312-B1 | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) | RATIOPHARM GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8936910-B2 | Method for selective oligonucleotide modification | ANTISENSE PHARMA GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140350047-A1 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-11-27 | — | — | US | disclosed |
| US-8853161-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140294762-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| EP-2279754-B1 | Remodelling and glycoconjugation of human growth hormone (hGH) | RATIOPHARM GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8791066-B2 | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] | NOVO NORDISK A/S (DK) | 2014-07-29 | — | — | US | disclosed |
| US-20140170728-A1 | Factor IX: Remodeling and Glycoconjugation of Factor IX | NOVO NORDISK A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| US-8722866-B2 | Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2014-05-13 | — | — | US | disclosed |
| US-8716239-B2 | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF | NOVO NORDISK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-8716240-B2 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NOVO NORDISK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| EP-2305313-B1 | Remodelling and glycoconjugation of interferon-alpha (IFNa) | RATIOPHARM GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2298354-B1 | Remodelling and glycoconjugation of interferon-beta | RATIOPHARM GMBH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2279755-B1 | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) | RATIOPHARM GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2674440-A2 | Multivalent immunoglobulin-based bioactive assemblies | IBC Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-1694347-B1 | Glycopegylated erythropoietin | BIOGENERIX AG (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130172238-A1 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION | ANTISENSE PHARMA GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130121955-A1 | METHODS AND COMPOSITIONS FOR STABILIZING THE MYOCARDIUM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130101675-A1 | Cross-Linked Non-Demineralized Collagenous Biomaterial | DUNEAS NICOLAAS (ZA) | 2013-04-25 | — | — | US | disclosed |
| EP-2580326-A1 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION | Antisense Pharma GmbH (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | BIOGENERIX AG (DE) | 2013-03-07 | — | — | US | disclosed |
| EP-1578771-B1 | Remodeling and glycoconjugation of peptides | NOVO NORDISK AS (DK) | 2013-03-06 | — | — | EP | disclosed |
| EP-1608688-B1 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | BIOGENERIX AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-1102785-B1 | COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | ARROWHEAD RES CORP (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8361961-B2 | O-linked glycosylation of peptides | BIOGENERIX AG (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8298606-B2 | Methods and compositions for stabilizing the myocardium | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | NOVO NORDISK A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| US-8247381-B2 | Branched water-soluble polymers and their conjugates | BIOGENERIX AG (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20120016105-A1 | PURIFICATION OF PEPTIDE CONJUGATES BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2012-01-19 | — | — | US | disclosed |
| EP-1624847-B1 | Compositions and methods for the preparation of human growth hormone glycosylation mutants | BIOGENERIX AG (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306657-A1 | POLYALKYLENEIMINE-GRAFT-BIODEGRADABLE POLYMERS FOR DELIVERY OF BIOACTIVE AGENTS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2011-12-15 | — | — | US | disclosed |
| US-8076292-B2 | Factor VIII: remodeling and glycoconjugation of factor VIII | NOVO NORDISK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-8063015-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| EP-1615945-B1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | BIOGENERIX AG (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-8008252-B2 | Factor VII: remodeling and glycoconjugation of Factor VII | NOVO NORDISK A/S (DK) | 2011-08-30 | — | — | US | disclosed |
| US-7985601-B2 | Drug delivery vehicle; tissue engineering | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110177029-A1 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | NOVO NORDISK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| EP-2338333-A2 | Glycopegylation methods and proteins/peptides produced by the methods | BioGeneriX AG (DE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2336159-A2 | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. | Abbott GmbH & Co. KG (DE) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336160-A2 | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. | Abbott GmbH & Co. KG (DE) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336161-A2 | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. | Abbott GmbH & Co. KG (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110136893-A1 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES | ANTISENSE PHARMA GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2322229-A2 | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) | NOVO NORDISK A/S (DK) | 2011-05-18 | — | — | EP | disclosed |
| US-7932364-B2 | Extended half life; reduced clearance and immunogenicity; industrial scale production; cells, expression cassettes | NOVO NORDISK A/S (DE) | 2011-04-26 | — | — | US | disclosed |
| EP-2305312-A2 | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) | BioGeneriX AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305314-A2 | Remodelling and glycoconjugation of antibodies | BioGeneriX AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305313-A2 | Remodelling and glycoconjugation of interferon-alpha (IFNa) | BioGeneriX AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305311-A2 | Glycoconjugation of peptides | BioGeneriX AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298354-A2 | Remodelling and glycoconjugation of interferon-beta | BioGeneriX AG (DE) | 2011-03-23 | — | — | EP | disclosed |
| EP-2292273-A2 | Remodeling and glycoconjugation of peptides | BioGeneriX AG (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292271-A2 | Remodelling and glycoconjugation of an antibody | BioGeneriX AG (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110046038-A1 | Polypeptide-Polymer Conjugates and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-24 | — | — | US | disclosed |
| EP-2279754-A2 | Remodelling and glycoconjugation of human growth hormone (hGH) | BioGeneriX AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279755-A2 | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) | BioGeneriX AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279753-A2 | Remodeling and glycoconjugation of peptides | Novo Nordisk A/S (DK) | 2011-02-02 | — | — | EP | disclosed |
| EP-2268673-A2 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100331489-A1 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | BIOGENERIX AG (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2010133975-A2 | REDUCIBLE POLYAMINO DISULFIDES AS TRANSFECTANTS | IMUTHES LIMITED (GB) | 2010-11-25 | — | — | WO | disclosed |
| US-20100286067-A1 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | BIOGENERIX AG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2242505-A2 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | BioGeneriX AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7820787-B2 | Multi-functional antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100266559-A1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | SYNOVIS ORTHOPEDIC AND WOUNDCARE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267046-A1 | ISOFORM-SELECTIVE INHIBITOR AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100261872-A1 | Factor VIII: remodeling and glycoconjugation of factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7803777-B2 | Branched water-soluble polymers and their conjugates | BIOGENERIX AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-1430140-B1 | N-TERMINALLY TRUNCATED ISOFORMS OF PDE3A CYCLIC PHOSPHODIESTERASES | UNIV UTAH (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7795210-B2 | Protein remodeling methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2010-09-14 | — | — | US | disclosed |
| US-7744816-B2 | Methods and device for biomolecule characterization | INTEL CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010049103-A1 | SOLUBLE TRUNCATED APOM PROTEINS AND MEDICAL USES THEREOF | ETH ZURICH (CH) | 2010-05-06 | — | — | WO | disclosed |
| EP-0958356-B1 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | MIRUS BIO CORP (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7696163-B2 | Forming a convalent conjugate of a peptide, EPO, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NOVO NORDISK A/S (DK) | 2010-04-13 | — | — | US | disclosed |
| EP-2162535-A2 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | Novo Nordisk A/S (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-20100048456-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2010-02-25 | — | — | US | disclosed |
| US-20100015684-A1 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII | NEOSE TECHNOLOGIES, INC. | 2010-01-21 | — | — | US | disclosed |
| EP-2121028-A2 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES | Antisense Pharma GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009120893-A2 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090196898-A1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | SYNOVIS LIFE TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2080525-A1 | Remodeling and Glycoconjugation of Peptides | BioGeneriX AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009089396-A2 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | NEOSE TECHNOLOGIES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| EP-1507561-B1 | COMPOSITIONS FOR DELIVERING NUCLEIC ACIDS TO CELLS | MIRUS BIO CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090169509-A1 | O-linked glycosylation of peptides | BIOGENERIX AG (DE) | 2009-07-02 | — | — | US | disclosed |
| WO-2009070787-A1 | METHODS FOR DETERMINING PRESENCE OF VASCULAR PLAQUES USING PRETARGETING REAGENT AND AB-SN CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090137763-A1 | GLUCOSAMINE NUCLEOTIDE SUGARS | NEOSE TECHNOLOGIES, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090124777-A1 | Compositions for Delivering Nucleic Acids to Cells | ROCHE MADISON INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090123412-A1 | Methods and compositions for stabilizing the myocardium | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009056330-A1 | SOLUBLE TRUNCATED APOM PROTEINS AND MEDICAL USES THEREOF | ETH ZURICH (CH) | 2009-05-07 | — | — | WO | disclosed |
| EP-2055189-A1 | Glycopegylation methods and proteins/peptides produced by the methods | Neose Technologies, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7528235-B2 | antibodies that recognize chelating agents | THE REGENTS OF THE UNIVARSITY OF CALIFORNIA (US) | 2009-05-05 | — | — | US | disclosed |
| EP-2049144-A2 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | Neose Technologies, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090093399-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093618-A1 | STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNA (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2042196-A2 | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) | Neose Technologies, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7498017-B2 | Compositions for delivering nucleic acids to cells | ROCHE MADISON INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7491263-B2 | Storage assembly | TECHNOLOGY INNOVATION, LLC (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090035828-A1 | Method For the Preparation of Cross Linked Protein Crystals | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-02-05 | — | — | US | disclosed |
| US-7473680-B2 | Forming a convalent conjugate of a peptide, EPO, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NEOSE TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7470539-B2 | Formation of polyampholytes in the presence of a polyion | ROCHE MADISON INC. | 2008-12-30 | — | — | US | disclosed |
| EP-2001521-A2 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | Pegasus Biologics, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080305991-A1 | Factor IX: remodeling and glycoconjugation of factor IX | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008151258-A2 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300175-A1 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300173-A1 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] | NOVO NORDISK A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| US-20080280818-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1841864-A4 | CHARGE NEUTRALIZATION OF POLYION COMPLEXES | MIRUS BIO CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080274958-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7439043-B2 | Galactosyl nucleotide sugars | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080255040-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080248959-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080242607-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242846-A1 | O-LINKED GLYCOSYLATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080206808-A1 | GALACTOSYL NUCLEOTIDE SUGAR | NEOSE TECHNOLOGIES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-7416858-B2 | Pharmaceutical compositions of glycoconjugates | NEOSE TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080200661-A1 | COMPOSITION FOR IN VIVO DELIVERY | ROZEMA DAVID B | 2008-08-21 | — | — | US | disclosed |
| US-20080187955-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7405198-B2 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7399613-B2 | Sialic acid nucleotide sugars | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2008077956-A2 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES | ANTISENSE PHARMA GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
| EP-1935428-A1 | Oligonucleotide-polymer conjugates | Antisense Pharma GmbH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146494-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| EP-1624847-A4 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | NEOSE TECHNOLOGIES INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080102083-A1 | Compositions and Methods for the Preparation of Human Growth Hormone Glycosylation Mutants | NEOSE TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080070275-A1 | Factor VIII: Remodeling and glycoconjugation of factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-0958356-A4 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | MIRUS BIO CORP (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7338933-B2 | Human Growth Hormone polypeptide comprising an O-linked glycosylation site that does not exist in a wild type polypeptide; glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked through the site | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080050772-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008011633-A2 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1869169-A2 | CONTROLLING STEM CELL DESTINY DESTINY WITH TUNABLE NETWORKS | The Regents of the University of California (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7297511-B2 | Viricides; heptatis virus; complexing of interferon with glycan | NEOSE TECHNOLOGIES, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2007131242-A2 | STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070254834-A1 | Glycopegylated Erythropoietin | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| EP-1841864-A2 | CHARGE NEUTRALIZATION OF POLYION COMPLEXES | Mirus Bio Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2007109180-A2 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | PEGASUS BIOLOGICS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070218038-A1 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED | PEGASUS BIOLOGICS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-7267994-B2 | Element-coded affinity tags | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-11 | — | — | US | disclosed |
| US-7265084-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265085-B2 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1507561-A4 | COMPOSITIONS FOR DELIVERING NUCLEIC ACIDS TO CELLS | MIRUS BIO CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1581622-A4 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7226903-B2 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7220400-B2 | Compositions for delivering nucleic acids to cells | MIRUS BIO CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-20070105192-A1 | Cyclodextrin affinity purification | NEOSE TECHNOLOGIES, INC. | 2007-05-10 | — | — | US | disclosed |
| US-7214660-B2 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214545-B2 | Element-coded affinity tags | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-08 | — | — | US | disclosed |
| US-7208314-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070082059-A1 | Cross-linked collagenous biomaterial | DUNEAS NICOLAAS | 2007-04-12 | — | — | US | disclosed |
| EP-1771066-A2 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 GLP-1 | Neose Technologies, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1765853-A2 | O-LINKED GLYCOSYLATION OF PEPTIDES | Neose Technologies, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070059275-A1 | Antibody toxin conjugates | NOVO NORDISK A/S (DK) | 2007-03-15 | — | — | US | disclosed |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. | 2007-02-22 | — | — | US | disclosed |
| EP-1578771-A4 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7179617-B2 | Forming a convalent conjugate of a Factor IX peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070032405-A1 | Branched water-soluble polymers and their conjugates | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7173003-B2 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070026485-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027068-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-20070026518-A1 | Controlling stem cell destiny with tunable matrices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-01 | — | — | US | disclosed |
| US-7157277-B2 | Factor VIII remodeling and glycoconjugation of Factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006138223-A2 | STORAGE ASSEMBLY | TECHNOLOGY INNOVATIONS, LLC (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287223-A1 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-7138371-B2 | customized in vitro glycosylation of peptides; industrial scale; modification of glycosylated and non-glycosylated peptides with modifying groups such as water-soluble polymers, therapeutic moieties, biomolecules | NEOSE TECHNOLOGIES, INC (US) | 2006-11-21 | — | — | US | disclosed |
| US-7138382-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1721603-A1 | Nanoparticles for bioconjugation | Albert-Ludwigs-Universität Freiburg (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-7125843-B2 | Glycoconjugates including more than one peptide | NEOSE TECHNOLOGIES, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7118745-B1 | Engineering antibodies that bind irreversibly | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-10 | — | — | US | disclosed |
| WO-2006105278-A2 | CONTROLLING STEM CELL DESTINY DESTINY WITH TUNABLE NETWORK | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060210571-A1 | Engineering antibodies that bind irreversibly | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1699921-A1 | A METHOD FOR THE PREPARATION OF CROSS LINKED PROTEIN CRYSTALS | Council of Scientific and Industrial Research;an Indian Reg. body incorporated under Reg. of Societies Act (Act XXI of 1860) (IN) | 2006-09-13 | — | — | EP | disclosed |
| US-7098032-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2006-08-29 | — | — | US | disclosed |
| US-7094605-B2 | Formation of polyampholytes in the presence of a polyion | MIRUS BIO CORPORATION (US) | 2006-08-22 | — | — | US | disclosed |
| WO-2006083342-A1 | FORMATION OF POLYAMPHOLYTES IN THE PRESENCE OF A POLYION | MIRUS BIO CORPORATION (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006081074-A2 | CHARGE NEUTRALIZATION OF POLYION COMPLEXES | MIRUS BIO CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060163752-A1 | Storage assembly | TECHNOLOGY INNOVATION, LLC | 2006-07-27 | — | — | US | disclosed |
| US-20060128814-A1 | Photolytic cross-linkable monomers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-15 | — | — | US | disclosed |
| US-20060088906-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2006-04-27 | — | — | US | disclosed |
| EP-1102785-A4 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | MIRUS CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022525-B2 | Process of making a compound by forming a polymer from a template drug | MIRUS BIO CORPORATION (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060063209-A1 | Engineered antibody fragment that irreversibly binds an antigen | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-23 | — | — | US | disclosed |
| US-20060063257-A1 | Formation of polyampholytes in the presence of a polyion | ROCHE MADISON INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060039860-A1 | Compositions for delivering nucleic acids to cells | ROCHE MADISON INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1624847-A2 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | Neose Technologies, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20060030521-A1 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-20060024828-A1 | Process of making a compound by forming a polymer from a template drug | ROCHE MADISON INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010143-A2 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | NEOSE TECHNOLOGIES, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1608688-A2 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | Neose Technologies, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050265956-A1 | Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2005-12-01 | — | — | US | disclosed |
| EP-1594891-A1 | AMYLOID-BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF, ANTIBODIES FOR THE SAME, METHOD FOR PRODUCTION AND USE THEROF | Abbott GmbH & Co. KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050250678-A1 | polypeptide (interferon, colony stimulating factor, human growth hormone) having an O-linked glycosylation site that does not exist in a wild type polypeptide; glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked through the site | NEOSE TECHNOLOGIES, INC. (US) | 2005-11-10 | — | — | US | disclosed |
| EP-1233671-A4 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING AMPHIPHILE BINDING MOLECULES | MIRUS CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1581622-A2 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | Neose Technologies, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578771-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | Neose Technologies, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050170505-A1 | Formation of polyampholytes in the presence of a polyion | ROCHE MADISON INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005070138-A2 | O-LINKED GLYCOSYLATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005066341-A1 | A METHOD FOR THE PREPARATION OF CROSS LINKED PROTEIN CRYSTALS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-07-21 | — | — | WO | disclosed |
| US-6919091-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050152986-A1 | Cross-linked collagenous biomaterial | BONE SA (ZA) | 2005-07-14 | — | — | US | disclosed |
| US-20050143292-A1 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | US | disclosed |
| EP-1218413-A4 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | UNIV CALIFORNIA (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050123600-A1 | Compositions and methods for drug delivery using pH sensitive molecules | ROCHE MADISON INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050106658-A1 | Remodeling and glycoconjugation of peptides | NOVO NORDISK A/S (DK) | 2005-05-19 | — | — | US | disclosed |
| US-20050100982-A1 | Forming a convalent conjugate of a Factor IX peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NEOSE TECHNOLOGIES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6881576-B2 | Formation of polyampholytes in the presence of a polyion | MIRUS BIO CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| US-20050059100-A1 | For detecting and analyzing oxidized polypeptides, nucleic acids, lipids, and polysaccharides; kits; neurodegenerative/neoplastic/vascular/autoimmune disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-03-17 | — | — | US | disclosed |
| US-20050042695-A1 | Element-coded affinity tags | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1507561-A2 | COMPOSITIONS FOR DELIVERING NUCLEIC ACIDS TO CELLS | Mirus Corporation (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050031584-A1 | Interleukin-2:remodeling and glycoconjugation of interleukin-2 | NEOSE TECHNOLOGIES, INC. | 2005-02-10 | — | — | US | disclosed |
| US-20050026263-A1 | Multi-functional antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1430140-A4 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC | UNIV UTAH (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004103275-A2 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | NEOSE TECHNOLOGIES, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004097372-A2 | ELEMENT-CODED AFFINITY TAGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040198962-A1 | Multi-functional antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004083258-A2 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | NEOSE TECHNOLOGIES INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040161463-A1 | Process of making a compound by forming a polymer from a template drug | Arrowhead Madison Inc. | 2004-08-19 | — | — | US | disclosed |
| WO-2004067561-A1 | AMYLOID-$G(B)(1-42) OLIGOMERS, DERIVATIVES THEREOF, ANTIBODIES FOR THE SAME, METHOD FOR PRODUCTION AND USE THEROF | ABBOTT GMBH & CO. KG (DE) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004065569-A2 | MULTI-FUNCTIONAL ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040146934-A1 | Multi-functional antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OFFICE OF TECHNOLOGY TRANSFER (US) | 2004-07-29 | — | — | US | disclosed |
| US-20040142856-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20040137557-A1 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040137625-A1 | Compositions and methods for drug delivery using amphiphile binding molecules | ROCHE MADISON INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040132640-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040126838-A1 | Follicle stimulating hormone: remodeling and glycoconjugation of FSH | NEOSE TECHNOLOGIES, INC. | 2004-07-01 | — | — | US | disclosed |
| EP-1430140-A2 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC | University of Utah (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6740643-B2 | GENE TRANSFER BY FORMING A COMPLEX OF AN AMPHIPHILE BINDING AGENT SUCH AS A CYCLODEXTRIN, AN AMPHIPHILE, AND A POLYNUCLEOTIDE, DELIVERING COMPLEX TO CELL AND EXPRESSING POLYNUCLEOTIDE; GENE THERAPY | MIRUS CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004033651-A2 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040058446-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Madison Inc. | 2004-03-25 | — | — | US | disclosed |
| US-6706922-B2 | FORMING A POLYMER IN THE PRESENCE OF A BIOLOGICALLY ACTIVE DRUG FOR DELIVERY TO A CELL; CATIONIC POLYAMINE COMPOUNDS FOR CONJUGATION WITH POLYETHYLENE GLYCOL AND COMPLEXING WITH NUCLEIC ACIDS | MIRUS CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040001892-A1 | Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-01 | — | — | US | disclosed |
| WO-2003099225-A2 | COMPOSITIONS FOR DELIVERING NUCLEIC ACIDS TO CELLS | MIRUS CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030220289-A1 | Compositions for delivering nucleic acids to cells | ROCHE MADISON INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030207326-A1 | Methods and device for biomolecule characterization | INTEL CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030199090-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Pharmaceuticals, Inc. | 2003-10-23 | — | — | US | disclosed |
| US-6630351-B1 | Transfecting a cell by attaching a reversible labile membrane activity inhibitor to a melittin peptide; adding peptide to solution containing the nucleic acid; endocytosis | MIRUS CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030158133-A1 | Use of such inhibitors or activators in treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2003-08-21 | — | — | US | disclosed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | disclosed |
| WO-2003031464-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003020327-A2 | A CROSS-LINKED COLLAGENOUS BIOMATERIAL | BONE SA (ZA) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003012030-A2 | ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC | UNIVERSITY OF UTAH, TECHNOLOGY TRANSFER OFFICE (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20030026841-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Madison Inc. | 2003-02-06 | — | — | US | disclosed |
| US-20020165184-A1 | Process of making a compound by forming a polymer from a template drug | ROCHE MADISON INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020160515-A1 | Formation of polyampholytes in the presence of a polyion | Arrowhead Madison Inc. | 2002-10-31 | — | — | US | disclosed |
| EP-1246532-A2 | DELIVERY OF SINGLE STRANDED DNA FOR EXPRESSION | Mirus Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020127535-A1 | Application of reversible crosslinking and co-treatment in stabilization and viral inactivation of erythrocytes | BAKALTCHEVA IRINA B (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| EP-1233671-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING AMPHIPHILE BINDING MOLECULES | Mirus Corporation (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6436705-B1 | TREATING WITH CARBON MONOXIDE GAS AND REVERSIBLE CROSSLINKING AGENT OF DIAMIDE OR DIMETHYL-3,3*-DITHIOBISPROPIONIMIDATE IN PRESENCE OF GLUCOSE, FRUCTOSE, SUCROSE, TREHALOSE, OR RAFFINOSE CRYOPROTECTANT; FREEZE DRYING; STORAGE STABILITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-08-20 | — | — | US | disclosed |
| EP-1222202-A2 | AB5 TOXIN B SUBUNIT MUTANTS WITH ALTERED CHEMICAL CONJUG ATION CHARACTERISTICS | Active Biotech AB (SE) | 2002-07-17 | — | — | EP | disclosed |
| EP-1218413-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | The Regents of the University of California (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6358678-B1 | TREATING ERYTHROCYTES WITH CARBON MONOXIDE GAS, REACTING WITH REVERSIBLE CROSSLINKING AGENT IN PRESENCE OF HIGH CONCENTRATION OF LOW MOLECULAR WEIGHT CRYOPROTECTANT, LYOPHILIZING, STORING AT ROOM TEMPERATURE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-03-19 | — | — | US | disclosed |
| EP-1073707-A4 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | MIRUS CORP (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1175395-A1 | METHOD OF PREPARING N,N'-DISUBSTITUTED-3,3'-DITHIODIPROPIONAMIDE AND METHOD OF PREPARING SUBSTITUTED 3-ISOTHIAZOLONE BY USING THE SAME | SK Chemicals Co., Ltd. (KR) | 2002-01-30 | — | — | EP | disclosed |
| US-6339067-B1 | COVALENTLY FORMING A POLYMER, FROM MONOMERS, IN PRESENCE OF A POLYION, WHEREIN THE POLYMER IS FORMED OUTSIDE OF ANY CELL, RESULTING IN POLYMER--POLYION COMPLEX FOR DELIVERY TO A CELL, WHEREIN POLYION IS NOT REMOVED FROM COMPLEX | MIRUS CORPORATION | 2002-01-15 | — | — | US | disclosed |
| US-20010044412-A1 | Compositions and methods for drug delivery using amphiphile binding molecules | ROCHE MADISON INC. | 2001-11-22 | — | — | US | disclosed |
| EP-1111069-A1 | Modified nucleic acids and their use | BioChip Technologies GmbH (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001037665-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING AMPHIPHILE BINDING MOLECULES | MIRUS CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1102785-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | Mirus Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001027144-A2 | AB5 TOXIN B SUBUNIT MUTANTS WITH ALTERED CHEMICAL CONJUGATION CHARACTERISTICS | ACTIVE BIOTECH AB (SE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001022922-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1073707-A1 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | Mirus Corporation (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000075164-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000074635-A2 | DELIVERY OF SINGLE STRANDED DNA FOR EXPRESSION | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000059879-A1 | METHOD OF PREPARING N,N'-DISUBSTITUTED-3,3'-DITHIODIPROPIONAMIDE AND METHOD OF PREPARING SUBSTITUTED 3-ISOTHIAZOLONE BY USING THE SAME | SK CHEMICALS CO., LTD ET AL. (KR) | 2000-10-12 | — | — | WO | disclosed |
| EP-0958356-A1 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | Mirus Corporation (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999055825-A1 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | MIRUS CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5925736-A | COLLAGEN MOLECULE CROSSLINKED TO MUCOSA BINDING MOLECULE | FIBROGEN, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998029541-A1 | A PROCESS OF MAKING A COMPOUND BY FORMING A POLYMER FROM A TEMPLATE DRUG | MIRUS CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0805686-A1 | COLLAGEN-BASED METHODS AND FORMULATIONS FOR THE TREATMENT OF IMMUNE SYSTEM-MEDIATED DISEASES | FIBROGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5686071-A | Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease | PER IMMUNE HOLDINGS, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1996021458-A1 | COLLAGEN-BASED METHODS AND FORMULATIONS FOR THE TREATMENT OF IMMUNE SYSTEM-MEDIATED DISEASES | FIBROGEN, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0304934-A2 | Labelled molecular probes, their production and use | Hunger, Hans-Dieter (DE) | 1989-03-01 | — | — | EP | disclosed |
| WO-1988008875-A1 | CYCLING BIOCHIP SENSOR | THE WASHINGTON TECHNOLOGY CENTER (US) | 1988-11-17 | — | — | WO | disclosed |
| US-4748121-A | Porous glass fibers with immobilized biochemically active material | PPG INDUSTRIES, INC. (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0095907-B1 | BIOCIDAL OR BIOSTATIC COMPOSITIONS CONTAINING 3-ISOTHIAZOLONES, THEIR METHOD OF PREPARATION AND THEIR USES | ROHM AND HAAS COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4665089-A | IMIDOESTER OR N-HYDROXYSUCCINIMIDE ESTER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0199103-A2 | Process for preventing or reversing cataract formation using protein modification reagents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4608246-A | Testing for a blood group immunological reaction | IMMUCOR, INC. (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0183207-A1 | Porous glass fibers with immobilized biochemically active material | PPG INDUSTRIES, INC. (US) | 1986-06-04 | — | — | EP | disclosed |
| US-4511501-A | Bis-amide disulfide cleavable cross-linking reagents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0095907-A2 | Biocidal or biostatic compositions containing 3-isothiazolones, their method of preparation and their uses | ROHM AND HAAS COMPANY (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4371612-A | Immobilization of biological material with an acrylonitrile polymer | TOYO JOZO COMPANY, LTD. (JP) | 1983-02-01 | — | — | US | disclosed |
| US-4371612-A | Immobilization of biological material with an acrylonitrile polymer | TOYO JOZO COMPANY, LTD. (JP) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248959-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | TSHR 2283/4885LMNA 4023/4885 |
| US-20200338210-A1 | ANTI-ROR1 ANTIBODY AND CONJUGATES THEREOF | RORA, RORB, RORC | TSHR 1245/4885LMNA 3777/4885 |
| US-20240277830-A1 | CORONAVIRUS VACCINE | ACE2, LNPEP, ACE | TSHR 4385/4885LMNA 575/4885 |
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | IL2, CCR10, IL2RA | TSHR 1302/4885LMNA 3054/4885 |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | TSHR 2765/4885LMNA 126/4885 |
| US-11583591-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TSHR 3162/4885LMNA 52/4885 |
| US-20240335516-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) | SMN1; SMN2, SNRPB2, SYNCRIP | TSHR 4335/4885LMNA 287/4885 |
| US-11028179-B2 | Anti-transferrin receptor antibodies and uses thereof | TFRC, FOLR1, CD47 | TSHR 19/4885LMNA 4483/4885 |
| US-20180250424-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | MRE11, DCLRE1A, RAD51 | TSHR 4732/4885LMNA 338/4885 |
| US-11918643-B2 | RNA vaccine against SARS-CoV-2 variants | ACE2, LNPEP, SARS1 | TSHR 4154/4885LMNA 1032/4885 |
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | IL2, CCR10, IL2RA | TSHR 1302/4885LMNA 3054/4885 |
| US-12325854-B2 | Crispr-CPF1-related methods, compositions and components for cancer immunotherapy | TP53, DCAF1, RTF1 | TSHR 4791/4885LMNA 2598/4885 |
| US-11253607-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TSHR 3162/4885LMNA 52/4885 |
| US-20200282074-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | TSHR 2765/4885LMNA 126/4885 |
| US-11596686-B2 | Coronavirus vaccine | ACE2, LNPEP, ACE | TSHR 4385/4885LMNA 575/4885 |
| US-11364302-B1 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | TSHR 2305/4885LMNA 269/4885 |
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | GLP1R, GIPR, IAPP | TSHR 576/4885LMNA 2567/4885 |
| US-20190345490-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | DCLRE1B, MPG, FEN1 | TSHR 3526/4885LMNA 1719/4885 |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | TSHR 2305/4885LMNA 269/4885 |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, ADAR | TSHR 3558/4885LMNA 94/4885 |
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | HLA-C, HLA-DRB1, HLA-B | TSHR 4793/4885LMNA 3028/4885 |
| US-20250281537-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST | IL15RA, IL15, IL2RA | TSHR 382/4885LMNA 3128/4885 |
| US-20260008990-A1 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | MEF2D, IL2, PDCD1LG2 | TSHR 1892/4885LMNA 616/4885 |
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | TSHR 972/4885LMNA 3865/4885 |
| US-20100261872-A1 | Factor VIII: remodeling and glycoconjugation of factor VIII | F13B, F8, F13A1 | TSHR 2265/4885LMNA 974/4885 |
| US-11872287-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TSHR 3162/4885LMNA 52/4885 |
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | GAP43, NGF, PMP22 | TSHR 4504/4885LMNA 280/4885 |
| US-11497814-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TSHR 3162/4885LMNA 52/4885 |
| US-20200123261-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | TSHR 2248/4885LMNA 280/4885 |
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | IL15, IL15RA, IL2 | TSHR 1111/4885LMNA 3721/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | TSHR 522/4885LMNA 4350/4885 |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | UPF1, RPRD2, NR2E3 | TSHR 861/4885LMNA 718/4885 |
| US-20240156949-A1 | Nucleic Acid Based Vaccine | ACE2, LNPEP, SARS1 | TSHR 4511/4885LMNA 620/4885 |
| US-20220211838-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | LNPEP, SARNP, PCNP | TSHR 2342/4885LMNA 443/4885 |
| US-11246941-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TSHR 3162/4885LMNA 52/4885 |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | TSHR 579/4885LMNA 1079/4885 |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | TSHR 3291/4885LMNA 68/4885 |
| US-20220047637-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HBG2, HBG1, HBB | TSHR 2539/4885LMNA 218/4885 |
| US-11311627-B1 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | NSUN2, UPF1, SNRPE | TSHR 2765/4885LMNA 126/4885 |
| US-20240287453-A1 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | CD47, CD74, HLA-DRB1 | TSHR 4396/4885LMNA 4826/4885 |
| US-11400163-B2 | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | NSUN2, UPF1, SNRPE | TSHR 2765/4885LMNA 126/4885 |
| US-20210379181-A1 | CORONAVIRUS VACCINE | ACE2, LNPEP, ACE | TSHR 4385/4885LMNA 575/4885 |
| US-20170073674-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | NR2E3, RB1, ALDH1A2 | TSHR 4089/4885LMNA 154/4885 |
| US-20260108590-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | HBG1, HBB, HBG2 | TSHR 2138/4885LMNA 316/4885 |
| US-20240066114-A1 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | LNPEP, SARS1, LNPK | TSHR 3964/4885LMNA 589/4885 |
| US-20020165184-A1 | Process of making a compound by forming a polymer from a template drug | PML, POLRMT, POLR2E | TSHR 4347/4885LMNA 181/4885 |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | TSHR 3793/4885LMNA 81/4885 |
| US-20230302122-A1 | CORONAVIRUS VACCINE | ACE2, LNPEP, ACE | TSHR 4385/4885LMNA 575/4885 |
| US-10550188-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | TSHR 2248/4885LMNA 280/4885 |
| US-20260060996-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | UPF1, FUS, TFRC | TSHR 116/4885LMNA 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.